Pubblicazioni

Autori:

Gargiulo, Luigi; Ibba, Luciano; Alfano, Angela; Malagoli, Piergiorgio; Amoruso, Fabrizio; Balato, Anna; Barei, Francesca; Burroni, Anna G.; Caccavale, Stefano; Calzavara-Pinton, Piergiacomo; Esposito, Maria; Fargnoli, Maria C.; Ferrucci, Silvia M.; Foti, Caterina; Girolomoni, Giampiero; Gola, Massimo; Guanti, Mario B.; Gurioli, Carlotta; Magliulo, Manfredi; Maurelli, Martina; Morrone, Pietro; Musumeci, Maria L.; Napolitano, Maddalena; Ortoncelli, Michela; Patruno, Cataldo; Piraccini, Bianca M.; Pezzolo, Elena; Ribero, Simone; Rossi, Mariateresa; Savoia, Paola; Sciarrone, Claudio; Tirone, Benedetta; Vaccino, Marco; Veronese, Federica; Costanzo &, Antonio; Narcisi, Alessandra

Titolo:

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

The Journal of dermatological treatment.

ISSN Rivista:

1471-1753

Intervallo pagine:

1-5

Parole chiave:

Abrocitinib; atopic dermatitis; JAK inhibitors

Breve descrizione dei contenuti:

Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with moderate-to-severe AD. Our retrospective study included 85 adult patients from 14 Italian Dermatology Units affected by moderate-to-severe AD treated with abrocitinib 100/200mg. Methods: Effectiveness of abrocitinib at weeks 4 and 16 was assessed by using the Eczema Area and Severity Index (EASI), the Investigator Global Assessment (IGA), the peak pruritus and sleep- Numerical Rating Scale (PP-NRS and S-NRS, respectively). Results: At week 16, improvement of at least 90% in EASI (EASI90) and IGA 0/1 was observed in 49.4% and 61.2% of patients, respectively. A reduction of at least 4 points in PP-NRS and S-NRS compared with baseline was achieved by 70.6% of patients for both endpoints. No significant safety reports were observed during the study period. Naïve patients had better rates of EASI 90 compared to patients who previously failed dupilumab. Conclusion: Our data confirm the effectiveness of abrocitinib in a real-world setting with better clinical responses at weeks 4 and 16, compared with Phase-III clinical trials. Longer analyses are required to further establish the safety profile of abrocitinib.

Id prodotto:

141812

Handle IRIS:

11562/1142946

ultima modifica:

20 dicembre 2024

Citazione bibliografica:

Gargiulo, Luigi; Ibba, Luciano; Alfano, Angela; Malagoli, Piergiorgio; Amoruso, Fabrizio; Balato, Anna; Barei, Francesca; Burroni, Anna G.; Caccavale, Stefano; Calzavara-Pinton, Piergiacomo; Esposito, Maria; Fargnoli, Maria C.; Ferrucci, Silvia M.; Foti, Caterina; Girolomoni, Giampiero; Gola, Massimo; Guanti, Mario B.; Gurioli, Carlotta; Magliulo, Manfredi; Maurelli, Martina; Morrone, Pietro; Musumeci, Maria L.; Napolitano, Maddalena; Ortoncelli, Michela; Patruno, Cataldo; Piraccini, Bianca M.; Pezzolo, Elena; Ribero, Simone; Rossi, Mariateresa; Savoia, Paola; Sciarrone, Claudio; Tirone, Benedetta; Vaccino, Marco; Veronese, Federica; Costanzo &, Antonio; Narcisi, Alessandra, Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis « The Journal of dermatological treatment.» , 2024 , pp. 1-5

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo